Endocrinology and Metabolism

Paulette N. Dominguez (Dominguez PN)

1 Article

Clinical Study
Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults: Abigail U. Canto, Paulette N. Dominguez, Cecilia A. Jimeno, Jerry M. Obaldo, Ruben V. Ogbac; Endocrinol Metab. 2016;31(1):168-173. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.168

5,079 View
56 Download
12 Web of Science
13 Crossref

Background

Radioactive iodine as a treatment modality has been shown in several studies to be a safe and effective therapy for Graves disease. However, there is still no uniformity regarding optimal dosing method. The aim of this study is to compare the efficacy of calculated and fixed dosing of radioiodine for the treatment of Graves disease.

Methods

A hundred twenty-two patients diagnosed with Graves disease were randomized to receive either fixed or calculated dose of radioiodine. Those randomized to fixed activity received either low fixed activity at 9.9 mCi for thyroid gland size <40 g or high fixed activity at 14.9 mCi for thyroid gland size 40 to 80 g, and those grouped to calculated activity received 160 µCi/g of thyroid tissue adjusted for 24 hours radioiodine uptake. Thyroid function tests (free thyroxine [T4] and thyroid stimulating hormone [TSH]) were monitored at 10, 16, and 24 weeks after radioactive iodine therapy. The primary outcome, treatment failure was defined as persistently elevated free T4 and low TSH.

Results

Of the 122 patients randomized, 56 in the fixed dose group and 56 in the calculated dose group completed the follow-up. At the end of 6 months, the percentage of treatment failure was 37.50% in the calculated dose group versus 19.64% in the fixed dose group with a relative risk of 0.53 (95% confidence interval, 0.28 to 0.98) favoring the fixed dose group.

Conclusion

Fixed dose radioiodine has a significantly lower incidence of persistent hyperthyroidism at 6 months post-radioactive therapy.

Citations

Citations to this article as recorded by

The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
Felix Quataert, Bert Bravenboer, Marleen Keyaerts, Corina Emilia Andreescu
Hormone and Metabolic Research.2024; 56(02): 134. CrossRef
A retrospective study with long term follow-up of Graves' disease patients treated with low activities of 131Iodine
Regina NEUMANN, Robert THOMANN, Gerhard W. GOERRES
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2024;[Epub] CrossRef
Outcome and incidence of hypothyroidism in low-dose radioactive iodine treatment for hyperthyroidism
Ku-Hung Lin, Jiun-Chang Wu, Ming-Che Wu
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2024; : 500056. CrossRef
Possibility analysis of thyroid imaging parameters for dose adjustment in 131I treatment of hyperthyroidism
Xiaonan ZHANG, Junhong LI, Hui ZHOU, Qiteng LU, Hailian WEI, Aifeng LI, Xinyu WEI, Zhixiao WEI
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub] CrossRef
Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience
Busra Kuyumcu Demir, Ersen Karakilic, Emre Sedar Saygili, Nilgun Araci, Semra Ozdemir
Endocrine Practice.2022; 28(8): 749. CrossRef
Changes in Radiosensitivity to Gamma-Rays of Lymphocytes from Hyperthyroid Patients Treated with I-131
Valentina Dini, Massimo Salvatori, Mauro Belli, Maria Elena Lago, Alessandra Nosdeo, Donatella Pia Dambra, Luisa Lo Conte, Ilaria Pecchia, Alessandro Giordano
International Journal of Molecular Sciences.2022; 23(17): 10156. CrossRef
Current controversies in the management of Graves’ hyperthyroidism
Niroshan Francis, Thanuya Francis, John H Lazarus, Onyebuchi E Okosieme
Expert Review of Endocrinology & Metabolism.2020; 15(3): 159. CrossRef
Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves’ Ophthalmopathy
Shahrara Ariamanesh, Narjess Ayati, Zahra Mazloum Khorasani, Zohreh Mousavi, Victoria Kiavash, Zahra Kiamanesh, Seyed Rasoul Zakavi
Clinical Nuclear Medicine.2020; 45(7): 514. CrossRef
The relationship between thyroid eye disease and radioiodine treatment
Sarameth Thou, Sobhan Vinjamuri
Nuclear Medicine Communications.2019; 40(3): 194. CrossRef
99mTc-pertechnetate thyroid scintigraphy predicts clinical outcomes in personalized radioiodine treatment for Graves’ disease
Zhao Lina, Zhang Wenqi, Xin Yubo, Wen Qiang, Bail Lin, Guan Feng, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2018; 37(6): 349. CrossRef
Predicción de los resultados clínicos en el tratamiento personalizado con yodo radiactivo de la enfermedad de Graves, mediante gammagrafía tiroidea con 99mTc-pertecnetato
L. Zhao, W. Zhang, Y. Xin, Q. Wen, L. Bail, F. Guan, Ji Bin
Revista Española de Medicina Nuclear e Imagen Molecular.2018; 37(6): 349. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders
Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
Nuclear Medicine Communications.2017; 38(9): 756. CrossRef

Author index